PERSPECTIVE THERAPEUTICS, INC. Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent
PERSPECTIVE THERAPEUTICS, INC. (CATX) reported Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent of -2.70% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch · last filed 2026-03-16
- PERSPECTIVE THERAPEUTICS, INC. effective income tax rate reconciliation, tax credit, research, percent for fiscal 2025 was -2.70%.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent 12 month |
|---|---|
| 2025-12-31 | -2.70% 10-K · filed 2026-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |